Related Experiment Video
Updated: Oct 10, 2025
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
NPM1 is a Novel Therapeutic Target and Prognostic Biomarker for Ewing Sarcoma
Yangfan Zhou1, Yuan Fang1, Junjie Zhou1
1The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Abstract:
Ewing sarcoma (ES) is a cancer that may originate from stem mesenchymal or neural crest cells and is highly prevalent in children and adolescents. In recent years, targeted therapies against immune-related genes have shown good efficacy in a variety of cancers. However, effective targets for immunotherapy in ES are yet to be developed. In our study, we first identified the immune-associated differential hub gene NPM1 by bioinformatics methods as a differentially expressed gene, and then validated it using real time-PCR and western blotting, and found that this gene is not only closely related to the immune infiltration in ES, but also can affect the proliferation and apoptosis of ES cells, and is closely related to the survival of patients. The results of our bioinformatic analysis showed that NPM1 can be a hub gene in ES and an immunotherapeutic target to reactivate immune infiltration in patients with ES. In addition, treatment with NPM1 promoted apoptosis and inhibited the proliferation of ES cells. The NPM1 inhibitor NSC348884 can induce apoptosis of ES cells in a dose-dependent manner and is expected to be a potential therapeutic agent for ES.
Insights
New research identifies NPM1 as a key immune-related gene in Ewing sarcoma (ES). Targeting NPM1 may enhance immune infiltration and offers a potential therapeutic strategy for this pediatric cancer.
Area of Science:
- Oncology
- Immunology
- Genetics
Background:
- Ewing sarcoma (ES) is a prevalent pediatric cancer with limited effective immunotherapy targets.
- Recent advances in targeted therapies highlight the potential of immune-related genes in cancer treatment.
Purpose of the Study:
- To identify novel immune-associated genes as potential therapeutic targets for Ewing sarcoma.
- To investigate the role of NPM1 in ES immune infiltration, cell proliferation, and apoptosis.
Main Methods:
- Bioinformatic analysis to identify differentially expressed immune-associated hub genes.
- Validation using real-time PCR and Western blotting.
- Assessment of NPM1's impact on ES cell proliferation, apoptosis, and immune infiltration.
Main Results:
- NPM1 was identified as a differentially expressed immune-associated hub gene in ES.
- NPM1 expression correlates with immune infiltration, patient survival, and affects ES cell proliferation and apoptosis.
- The NPM1 inhibitor NSC348884 demonstrated dose-dependent induction of apoptosis in ES cells.
Conclusions:
- NPM1 is a potential immunotherapeutic target for Ewing sarcoma, capable of reactivating immune infiltration.
- NPM1 inhibition shows promise as a therapeutic strategy for ES by promoting apoptosis and inhibiting proliferation.
More Related Videos
09:33Author Spotlight: Finding New Therapeutic Targets for Malignant Peripheral Nerve Sheath Tumor Through Genome-Scale shRNA Screens
Published on: August 25, 2023
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:38Mitogens and the Cell Cycle
02:23Abnormal Proliferation